


Seeking Novel Therapeutic Assets for Epilepsy

Grünenthal, a global leader in pain management and related diseases, is seeking **novel therapeutic compounds for the treatment of epilepsies** and related seizure disorders. In addition to seizure control, the team is interested in projects offering disease-modifying potential to improve, for example, cognition decline, anxiety, depression, and sleep disturbances.



Approaches of Interest:

- **All forms of epilepsy and seizure disorders** are of interest, including rare monogenic epilepsies and developmental and epileptic encephalopathies, such as Dravet and Lennox-Gastaut syndromes. **Drug-resistant epilepsy** and **indications with limited treatment options** are a particular priority
- Modalities of interest include **small molecules, oligonucleotide** and **RNA-based therapeutics**, and **peptides**
- Focus on therapeutics for **oral and systemic administration**. Intrathecal delivery will also be considered
- All targets are of interest. High-priority targets include EAAT2, AMPA TARP γ8, NKCC1, KCNT1, and Kv and Nav channels

Out of Scope:

- Viral gene therapy and cell therapy approaches
- Drug repurposing
- Therapeutics for intranasal administration
- Platform technologies and projects without an associated asset or chemical matter
- Clinical stage opportunities

Developmental Stages of Interest:

- Opportunities from **lead compound** through to **late preclinical**, including the IND-enabling stage, are within scope

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should contain the **therapeutic molecule's mode of action**, any **experimental validation**, how it is **differentiated from known approaches**, and the **status of the project**, including **funding requirements** for next steps. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Grünenthal is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.

Opportunities sought

-  Technologies
-  Centres of excellence
-  Research projects
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **2nd November 2026 - 11:59 pm GMT**

Have any questions?

Contact our team at campaigns@inpart.io



Grünenthal is a science-based, fully integrated pharmaceutical company leading in pain management. They have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide.